Skip to main content
Erschienen in: DGNeurologie 3/2021

13.04.2021 | Neuropathischer Schmerz | CME Zertifizierte Fortbildung

Morbus Fabry in der Neurologie

verfasst von: PD Dr. Tobias Böttcher, T. Duning

Erschienen in: DGNeurologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der M. Fabry ist eine vererbte, lysosomale Speichererkrankung mit klinischer Manifestation in vielen Organsystemen. In der Neurologie kann er seltene Ursache und Differenzialdiagnose häufiger Krankheitsbilder mit Symptomen des zentralen und/oder peripheren Nervensystems sein. Eine zeitnahe Diagnose und Therapie sind wichtig, um Symptome zu lindern, irreversible Organschäden zu vermeiden und letztlich Lebenserwartung und -qualität der Betroffenen zu verbessern.
Literatur
2.
Zurück zum Zitat Fabry J (1898) Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphilis 43:187–200CrossRef Fabry J (1898) Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphilis 43:187–200CrossRef
3.
Zurück zum Zitat Anderson W (1898) A case of “Angio-Keratoma”. Br J Dermatol 18:113–117CrossRef Anderson W (1898) A case of “Angio-Keratoma”. Br J Dermatol 18:113–117CrossRef
4.
Zurück zum Zitat Lyon MF (1961) Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190:372–373PubMedCrossRef Lyon MF (1961) Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190:372–373PubMedCrossRef
5.
Zurück zum Zitat Beck M (2006) Demographics of FOS—the Fabry outcome survey. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 16) Beck M (2006) Demographics of FOS—the Fabry outcome survey. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 16)
6.
Zurück zum Zitat Ortiz A, Germain DP, Desnick RJ et al (2018) Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 123:416–427PubMedCrossRef Ortiz A, Germain DP, Desnick RJ et al (2018) Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 123:416–427PubMedCrossRef
7.
Zurück zum Zitat Cairns T, Muntze J, Gernert J et al (2018) Hot topics in Fabry disease. Postgrad Med J 94:709–713PubMedCrossRef Cairns T, Muntze J, Gernert J et al (2018) Hot topics in Fabry disease. Postgrad Med J 94:709–713PubMedCrossRef
8.
Zurück zum Zitat Schäfer E, Baron K, Widmer U et al (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25:412PubMedCrossRef Schäfer E, Baron K, Widmer U et al (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25:412PubMedCrossRef
10.
Zurück zum Zitat Ries M, Gal A (2006) Genotype-phenotype correlation in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford (Chapter 34) Ries M, Gal A (2006) Genotype-phenotype correlation in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford (Chapter 34)
11.
Zurück zum Zitat Schiffmann R, Ries M (2005) Fabry’s disease—an important risk factor for stroke. Lancet 366:1754–1756PubMedCrossRef Schiffmann R, Ries M (2005) Fabry’s disease—an important risk factor for stroke. Lancet 366:1754–1756PubMedCrossRef
12.
Zurück zum Zitat Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40PubMedPubMedCentralCrossRef Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat van der Tol L, Smid BE, Poorthuis BJ et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9PubMedCrossRef van der Tol L, Smid BE, Poorthuis BJ et al (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9PubMedCrossRef
14.
Zurück zum Zitat Laney DA, Fernhoff PM (2008) Diagnosis of Fabry disease via analysis of family history. J Genet Couns 17:79–83PubMedCrossRef Laney DA, Fernhoff PM (2008) Diagnosis of Fabry disease via analysis of family history. J Genet Couns 17:79–83PubMedCrossRef
15.
Zurück zum Zitat Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184–192PubMedCrossRef Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184–192PubMedCrossRef
16.
Zurück zum Zitat MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760PubMedPubMedCentralCrossRef MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775PubMedPubMedCentralCrossRef MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Miners AH, Holmes A, Sherr L et al (2002) Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res 11:127–133PubMedCrossRef Miners AH, Holmes A, Sherr L et al (2002) Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res 11:127–133PubMedCrossRef
19.
Zurück zum Zitat Lidove O, Jaussaud R, Aractingi S (2006) Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 24) Lidove O, Jaussaud R, Aractingi S (2006) Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 24)
20.
Zurück zum Zitat Larralde M, Boggio P, Amartino H et al (2004) Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. Arch Dermatol 140:1440–1446PubMedCrossRef Larralde M, Boggio P, Amartino H et al (2004) Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. Arch Dermatol 140:1440–1446PubMedCrossRef
21.
Zurück zum Zitat Lao LM, Kumakiri M, Mima H et al (1998) The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 18:109–117PubMedCrossRef Lao LM, Kumakiri M, Mima H et al (1998) The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 18:109–117PubMedCrossRef
22.
Zurück zum Zitat Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91:38–42PubMedCrossRef Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91:38–42PubMedCrossRef
23.
Zurück zum Zitat Köping M, Shehata-Dieler W, Schneider D et al (2018) Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet J Rare Dis 13:137–145PubMedPubMedCentralCrossRef Köping M, Shehata-Dieler W, Schneider D et al (2018) Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet J Rare Dis 13:137–145PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Sodi A, Ioannidis AS, Mehta A et al (2007) Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol 91:210–214PubMedCrossRef Sodi A, Ioannidis AS, Mehta A et al (2007) Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br J Ophthalmol 91:210–214PubMedCrossRef
25.
Zurück zum Zitat Pitz S, Grube-Einwald K, Renieri G et al (2009) Subclinical optic neuropathy in Fabry disease. Ophthalmic Genet 30:165–171PubMedCrossRef Pitz S, Grube-Einwald K, Renieri G et al (2009) Subclinical optic neuropathy in Fabry disease. Ophthalmic Genet 30:165–171PubMedCrossRef
26.
Zurück zum Zitat Hilz MJ, Arbustini E, Dagna L et al (2018) Non-specific gastrointestinal features: could it be Fabry disease? Dig Liver Dis 50:429–437PubMedCrossRef Hilz MJ, Arbustini E, Dagna L et al (2018) Non-specific gastrointestinal features: could it be Fabry disease? Dig Liver Dis 50:429–437PubMedCrossRef
27.
Zurück zum Zitat Linhart A (2006) The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford (Chapter 20) Linhart A (2006) The heart in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford (Chapter 20)
28.
Zurück zum Zitat Tanislav C, Guenduez D, Liebetrau C et al (2016) Cardiac troponin I: a valuable biomarker indicating the cardiac involvement in Fabry disease. PLoS ONE 11:e157640PubMedPubMedCentralCrossRef Tanislav C, Guenduez D, Liebetrau C et al (2016) Cardiac troponin I: a valuable biomarker indicating the cardiac involvement in Fabry disease. PLoS ONE 11:e157640PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Waldek S, Patel MR, Banikazemi M et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790–796PubMedCrossRef Waldek S, Patel MR, Banikazemi M et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790–796PubMedCrossRef
30.
Zurück zum Zitat Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122–138PubMedCrossRef Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122–138PubMedCrossRef
31.
Zurück zum Zitat Del Pino M, Andrés A, Bernabéu AÁ et al (2018) Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney Blood Press Res 43:406–421PubMedCrossRef Del Pino M, Andrés A, Bernabéu AÁ et al (2018) Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney Blood Press Res 43:406–421PubMedCrossRef
32.
Zurück zum Zitat Cybulla M et al (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45(5):E82–E89CrossRefPubMed Cybulla M et al (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45(5):E82–E89CrossRefPubMed
33.
34.
Zurück zum Zitat Fellgiebel A, Müller MJ, Ginsberg L (2006) CNS manifestations of Fabry’s disease. Lancet Neurol 5:791–795PubMedCrossRef Fellgiebel A, Müller MJ, Ginsberg L (2006) CNS manifestations of Fabry’s disease. Lancet Neurol 5:791–795PubMedCrossRef
35.
Zurück zum Zitat Fellgiebel A, Wolf DO, Kolodny E et al (2012) Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. J Inherit Metab Dis 35:363–367PubMedCrossRef Fellgiebel A, Wolf DO, Kolodny E et al (2012) Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. J Inherit Metab Dis 35:363–367PubMedCrossRef
36.
Zurück zum Zitat Barbey F, Brakch N, Linhart A et al (2006) Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl 95:63–68PubMedCrossRef Barbey F, Brakch N, Linhart A et al (2006) Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl 95:63–68PubMedCrossRef
37.
Zurück zum Zitat Rombach SM, Twickler TB, Aerts JM et al (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 99:99–108PubMedCrossRef Rombach SM, Twickler TB, Aerts JM et al (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 99:99–108PubMedCrossRef
38.
Zurück zum Zitat Böttcher T, Rolfs A, Tanislav C et al (2013) Fabry disease—underestimated in the differential diagnosis of multiple sclerosis? Plos One 8:e71894PubMedPubMedCentralCrossRef Böttcher T, Rolfs A, Tanislav C et al (2013) Fabry disease—underestimated in the differential diagnosis of multiple sclerosis? Plos One 8:e71894PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Lidove O, Chauveheid MP, Caillaud C et al (2009) Aseptic meningitis and ischaemic stroke in Fabry disease. Int J Clin Pract 63:1663–1667PubMedCrossRef Lidove O, Chauveheid MP, Caillaud C et al (2009) Aseptic meningitis and ischaemic stroke in Fabry disease. Int J Clin Pract 63:1663–1667PubMedCrossRef
40.
Zurück zum Zitat Sims K, Politei J, Banikazemi M et al (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40:788–794PubMedCrossRef Sims K, Politei J, Banikazemi M et al (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40:788–794PubMedCrossRef
41.
Zurück zum Zitat Moore DF, Herscovitch P, Schiffmann R (2001) Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 11:303–307PubMedCrossRef Moore DF, Herscovitch P, Schiffmann R (2001) Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 11:303–307PubMedCrossRef
42.
Zurück zum Zitat Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 94:24–27PubMedCrossRef Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 94:24–27PubMedCrossRef
43.
Zurück zum Zitat Kolodny E, Fellgiebel A, Hilz MJ et al (2015) Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 46:302–313PubMedCrossRef Kolodny E, Fellgiebel A, Hilz MJ et al (2015) Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 46:302–313PubMedCrossRef
44.
Zurück zum Zitat Schiffmann R, Moore D (2006) Nervous system manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 22) Schiffmann R, Moore D (2006) Nervous system manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 22)
45.
Zurück zum Zitat Rolfs A, Fazekas F, Grittner U et al (2013) Acute cerebrovascular disease in the young: the stroke in Young Fabry Patients study. Stroke 44:340–349PubMedCrossRef Rolfs A, Fazekas F, Grittner U et al (2013) Acute cerebrovascular disease in the young: the stroke in Young Fabry Patients study. Stroke 44:340–349PubMedCrossRef
46.
Zurück zum Zitat Desnik RJ, Bishop DF (1989) Fabry’s disease: Alpha-Galactosidase deficiency. In: Scriver CR, Beaudet AL, Sly WS, al (Hrsg) The metabolic basis of inherited disease. McGraw-Hill,, New York, S 1699–1720 Desnik RJ, Bishop DF (1989) Fabry’s disease: Alpha-Galactosidase deficiency. In: Scriver CR, Beaudet AL, Sly WS, al (Hrsg) The metabolic basis of inherited disease. McGraw-Hill,, New York, S 1699–1720
47.
Zurück zum Zitat Sigmundsdottir L, Tchan MC, Knopman AA et al (2014) Cognitive and psychological functioning in Fabry disease. Arch Clin Neuropsychol 29:642–650PubMedPubMedCentralCrossRef Sigmundsdottir L, Tchan MC, Knopman AA et al (2014) Cognitive and psychological functioning in Fabry disease. Arch Clin Neuropsychol 29:642–650PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Cole AL, Lee PJ, Hughes DA et al (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943–951PubMedCrossRef Cole AL, Lee PJ, Hughes DA et al (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943–951PubMedCrossRef
49.
Zurück zum Zitat Schiffmann R (2006) Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg 106:61–65PubMed Schiffmann R (2006) Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg 106:61–65PubMed
50.
Zurück zum Zitat Sommer C, Üçeyler N (2018) Small-Fiber-Neuropathien. Fortschr Neurol Psychiatr 86:509–518PubMedCrossRef Sommer C, Üçeyler N (2018) Small-Fiber-Neuropathien. Fortschr Neurol Psychiatr 86:509–518PubMedCrossRef
51.
Zurück zum Zitat Hoffmann B, Beck M, Sunder-Plassmann G et al (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy—a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535–542PubMedCrossRef Hoffmann B, Beck M, Sunder-Plassmann G et al (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy—a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535–542PubMedCrossRef
52.
53.
Zurück zum Zitat Choi L, Vernon J, Kopach O et al (2015) The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett 594:163–168PubMedPubMedCentralCrossRef Choi L, Vernon J, Kopach O et al (2015) The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett 594:163–168PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Burlina AP, Sims KB, Politei JM et al (2011) Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 11:61–80PubMedPubMedCentralCrossRef Burlina AP, Sims KB, Politei JM et al (2011) Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 11:61–80PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242PubMedCrossRef Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242PubMedCrossRef
56.
Zurück zum Zitat Üçeyler N, Ganendiran S, Kramer D et al (2014) Characterization of pain in Fabry disease. Clin J Pain 30:915–920PubMedCrossRef Üçeyler N, Ganendiran S, Kramer D et al (2014) Characterization of pain in Fabry disease. Clin J Pain 30:915–920PubMedCrossRef
57.
Zurück zum Zitat Arning K, Naleschinski D, Maag R et al (2012) FabryScan: a screening tool for early detection of Fabry disease. J Neurol 259:2393–2400PubMedCrossRef Arning K, Naleschinski D, Maag R et al (2012) FabryScan: a screening tool for early detection of Fabry disease. J Neurol 259:2393–2400PubMedCrossRef
58.
Zurück zum Zitat Bundesministerium für Justiz (2009) Gesetz über genetische Untersuchungen beim Menschen (Gendiagnostikgesetz). Bundesgesetzblatt 50:2529–2538 Bundesministerium für Justiz (2009) Gesetz über genetische Untersuchungen beim Menschen (Gendiagnostikgesetz). Bundesgesetzblatt 50:2529–2538
59.
60.
61.
Zurück zum Zitat Winchester B, Young E (2006) Biochemical und genetic diagnosis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 18) Winchester B, Young E (2006) Biochemical und genetic diagnosis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 18)
62.
Zurück zum Zitat Linthorst GE, Vedder AC, Aerts JM et al (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201–203PubMedCrossRef Linthorst GE, Vedder AC, Aerts JM et al (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201–203PubMedCrossRef
63.
Zurück zum Zitat Lu YH, Huang PH, Wang LY et al (2018) Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry. J Hum Genet 63:1–8PubMedCrossRef Lu YH, Huang PH, Wang LY et al (2018) Improvement in the sensitivity of newborn screening for Fabry disease among females through the use of a high-throughput and cost-effective method, DNA mass spectrometry. J Hum Genet 63:1–8PubMedCrossRef
64.
Zurück zum Zitat Reisin R, Perrin A, García-Pavía P (2017) Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract 71:e12914CrossRef Reisin R, Perrin A, García-Pavía P (2017) Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract 71:e12914CrossRef
65.
Zurück zum Zitat Mehta A, Beck M, Eyskens F et al (2010) Fabry disease: a review of current management strategies. QJM 103:641–659PubMedCrossRef Mehta A, Beck M, Eyskens F et al (2010) Fabry disease: a review of current management strategies. QJM 103:641–659PubMedCrossRef
66.
Zurück zum Zitat Niemann M, Rolfs A, Störk S et al (2014) Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet 7:8–16PubMedCrossRef Niemann M, Rolfs A, Störk S et al (2014) Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet 7:8–16PubMedCrossRef
67.
Zurück zum Zitat van Breemen MJ, Rombach SM, Dekker N et al (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812:70–76PubMedCrossRef van Breemen MJ, Rombach SM, Dekker N et al (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812:70–76PubMedCrossRef
68.
Zurück zum Zitat Eng CM, Guffon N, Wilcox WR et al (2001) International collaborative Fabry disease study group. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med 345:9–16PubMedCrossRef Eng CM, Guffon N, Wilcox WR et al (2001) International collaborative Fabry disease study group. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med 345:9–16PubMedCrossRef
69.
Zurück zum Zitat Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRef Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRef
70.
Zurück zum Zitat Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86PubMedCrossRef Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86PubMedCrossRef
71.
Zurück zum Zitat Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996PubMedCrossRef Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996PubMedCrossRef
72.
Zurück zum Zitat Watt T, Burlina AP, Cazzorla C et al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12:703–712PubMedCrossRef Watt T, Burlina AP, Cazzorla C et al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med 12:703–712PubMedCrossRef
73.
Zurück zum Zitat Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838–844PubMedCrossRef Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838–844PubMedCrossRef
74.
Zurück zum Zitat Beck M, Hughes D, Kampmann C et al (2015) Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep 3:21–27PubMedPubMedCentralCrossRef Beck M, Hughes D, Kampmann C et al (2015) Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep 3:21–27PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Germain DP, Hughes DA, Nicholls K et al (2016) Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med 375:545–555PubMedCrossRef Germain DP, Hughes DA, Nicholls K et al (2016) Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med 375:545–555PubMedCrossRef
76.
Zurück zum Zitat Lenders M, Nordbeck P, Kurschat C et al (2020) Treatment of Fabry’s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS). Clin Pharmacol Ther 108:326–337PubMedCrossRef Lenders M, Nordbeck P, Kurschat C et al (2020) Treatment of Fabry’s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS). Clin Pharmacol Ther 108:326–337PubMedCrossRef
77.
Zurück zum Zitat Hughes DA, Nicholls K, Shankar SP et al (2017) Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54:288–296PubMedCrossRef Hughes DA, Nicholls K, Shankar SP et al (2017) Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 54:288–296PubMedCrossRef
78.
Zurück zum Zitat Banikazemi M, Ullman T, Desnick RJ (2005) Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85:255–259PubMedCrossRef Banikazemi M, Ullman T, Desnick RJ (2005) Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85:255–259PubMedCrossRef
79.
Zurück zum Zitat Schiffmann R, Floeter MK, Dambrosia JM et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710PubMedCrossRef Schiffmann R, Floeter MK, Dambrosia JM et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710PubMedCrossRef
80.
Zurück zum Zitat Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74PubMedPubMedCentralCrossRef Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Schiffmann R, Moore DF (2006) Neurological effects of enzyme replacement therapy in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 39) Schiffmann R, Moore DF (2006) Neurological effects of enzyme replacement therapy in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 39)
82.
Zurück zum Zitat Sunder-Plassmann G, Shankar S, Wilcox W et al (2019) Occurrence of cerebrovascular events during long-term treatment with migalastat in patients with Fabry disease. Presented at the 15th Annual WORLD Symposium™, Orlando, February 4–8 (Poster LB-49) Sunder-Plassmann G, Shankar S, Wilcox W et al (2019) Occurrence of cerebrovascular events during long-term treatment with migalastat in patients with Fabry disease. Presented at the 15th Annual WORLD Symposium™, Orlando, February 4–8 (Poster LB-49)
83.
Zurück zum Zitat Cabrera G, Politei J, Antongiovani N et al (2017) Effectiveness of enzyme replacement therapy in Fabry disease: long term experience in Argentina. Mol Genet Metab Rep 11:65–68PubMedPubMedCentralCrossRef Cabrera G, Politei J, Antongiovani N et al (2017) Effectiveness of enzyme replacement therapy in Fabry disease: long term experience in Argentina. Mol Genet Metab Rep 11:65–68PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512PubMedCrossRef Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512PubMedCrossRef
85.
Zurück zum Zitat Laney DA, Bennett RL, Clarke V et al (2013) Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns 22:555–564PubMedCrossRef Laney DA, Bennett RL, Clarke V et al (2013) Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. J Genet Couns 22:555–564PubMedCrossRef
86.
Zurück zum Zitat Wanner C, Arad M, Baron R et al (2018) European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 124:189–203PubMedCrossRef Wanner C, Arad M, Baron R et al (2018) European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 124:189–203PubMedCrossRef
87.
Zurück zum Zitat Hughes DA, Evans S, Milligan A et al (2006) A multidisciplinary approach to the care of patients with Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 35) Hughes DA, Evans S, Milligan A et al (2006) A multidisciplinary approach to the care of patients with Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (Hrsg) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford (Chapter 35)
Metadaten
Titel
Morbus Fabry in der Neurologie
verfasst von
PD Dr. Tobias Böttcher
T. Duning
Publikationsdatum
13.04.2021
Verlag
Springer Medizin
Erschienen in
DGNeurologie / Ausgabe 3/2021
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI
https://doi.org/10.1007/s42451-021-00339-1

Weitere Artikel der Ausgabe 3/2021

DGNeurologie 3/2021 Zur Ausgabe

Magazin

Magazin